Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1910 1
1913 1
1914 1
1957 1
1967 1
1970 1
1971 1
1978 3
1980 2
1981 3
1983 3
1984 4
1987 2
1989 3
1991 4
1992 1
1993 3
1994 4
1995 4
1996 8
1997 11
1998 15
1999 14
2000 12
2001 10
2002 10
2003 14
2004 21
2005 45
2006 34
2007 33
2008 35
2009 34
2010 41
2011 64
2012 53
2013 49
2014 52
2015 38
2016 31
2017 41
2018 44
2019 40
2020 31
2021 53
2022 56
2023 48
2024 40
2025 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

911 results

Results by year

Filters applied: . Clear all
Page 1
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, Lawrence Ford T, Gupta R, Hiepe F, Santiago M, Brohawn PZ, Berglind A, Tummala R; TULIP-1 study investigators. Furie RA, et al. Among authors: bruce in. Lancet Rheumatol. 2019 Dec;1(4):e208-e219. doi: 10.1016/S2665-9913(19)30076-1. Epub 2019 Nov 11. Lancet Rheumatol. 2019. PMID: 38229377
2021 DORIS definition of remission in SLE: final recommendations from an international task force.
van Vollenhoven RF, Bertsias G, Doria A, Isenberg D, Morand E, Petri MA, Pons-Estel BA, Rahman A, Ugarte-Gil MF, Voskuyl A, Arnaud L, Bruce IN, Cervera R, Costedoat-Chalumeau N, Gordon C, Houssiau FA, Mosca M, Schneider M, Ward MM, Alarcon G, Aringer M, Askenase A, Bae SC, Bootsma H, Boumpas DT, Brunner H, Clarke AE, Coney C, Czirják L, Dörner T, Faria R, Fischer R, Fritsch-Stork R, Inanc M, Jacobsen S, Jayne D, Kuhn A, van Leeuw B, Limper M, Mariette X, Navarra S, Nikpour M, Olesinska MH, Pons-Estel G, Romero-Diaz J, Rubio B, Schoenfeld Y, Bonfá E, Smolen J, Teng YKO, Tincani A, Tsang-A-Sjoe M, Vasconcelos C, Voss A, Werth VP, Zakharhova E, Aranow C. van Vollenhoven RF, et al. Among authors: bruce in. Lupus Sci Med. 2021 Nov;8(1):e000538. doi: 10.1136/lupus-2021-000538. Lupus Sci Med. 2021. PMID: 34819388 Free PMC article.
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H. Kalunian KC, et al. Among authors: bruce in. Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11. Arthritis Rheumatol. 2023. PMID: 36369793 Free PMC article. Clinical Trial.
Drug-Induced Interstitial Lung Disease: A Systematic Review.
Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, Giollo A, Wild JM, Waterton JC, Buch M, Linton K, Bruce IN, Leonard C, Bianchi S, Chaudhuri N. Skeoch S, et al. Among authors: bruce in. J Clin Med. 2018 Oct 15;7(10):356. doi: 10.3390/jcm7100356. J Clin Med. 2018. PMID: 30326612 Free PMC article. Review.
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
Vital EM, Merrill JT, Morand EF, Furie RA, Bruce IN, Tanaka Y, Manzi S, Kalunian KC, Kalyani RN, Streicher K, Abreu G, Tummala R. Vital EM, et al. Among authors: bruce in. Ann Rheum Dis. 2022 Jul;81(7):951-961. doi: 10.1136/annrheumdis-2021-221425. Epub 2022 Mar 25. Ann Rheum Dis. 2022. PMID: 35338035 Free PMC article. Clinical Trial.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Petri M, et al. Among authors: bruce in. Arthritis Rheum. 2012 Aug;64(8):2677-86. doi: 10.1002/art.34473. Arthritis Rheum. 2012. PMID: 22553077 Free PMC article.
Targeting DORIS Remission and LLDAS in SLE: A Review.
Parra Sánchez AR, van Vollenhoven RF, Morand EF, Bruce IN, Kandane-Rathnayake R, Weiss G, Tummala R, Al-Mossawi H, Sorrentino A. Parra Sánchez AR, et al. Among authors: bruce in. Rheumatol Ther. 2023 Dec;10(6):1459-1477. doi: 10.1007/s40744-023-00601-w. Epub 2023 Oct 5. Rheumatol Ther. 2023. PMID: 37798595 Free PMC article. Review.
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.
Furie RA, Bruce IN, Dörner T, Leon MG, Leszczyński P, Urowitz M, Haier B, Jimenez T, Brittain C, Liu J, Barbey C, Stach C. Furie RA, et al. Among authors: bruce in. Rheumatology (Oxford). 2021 Nov 3;60(11):5397-5407. doi: 10.1093/rheumatology/keab381. Rheumatology (Oxford). 2021. PMID: 33956056 Free PMC article. Clinical Trial.
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, Aringer M, Bootsma H, Boumpas D, Bruce IN, Cervera R, Clarke A, Costedoat-Chalumeau N, Czirják L, Derksen R, Dörner T, Gordon C, Graninger W, Houssiau F, Inanc M, Jacobsen S, Jayne D, Jedryka-Goral A, Levitsky A, Levy R, Mariette X, Morand E, Navarra S, Neumann I, Rahman A, Rovensky J, Smolen J, Vasconcelos C, Voskuyl A, Voss A, Zakharova H, Zoma A, Schneider M. van Vollenhoven RF, et al. Among authors: bruce in. Ann Rheum Dis. 2014 Jun;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139. Epub 2014 Apr 16. Ann Rheum Dis. 2014. PMID: 24739325
Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations.
Askanase AD, Furie RA, Dall'Era M, Bomback AS, Schwarting A, Zhao MH, Bruce IN, Khamashta M, Rubin B, Carroll A, Daniels M, Levy RA, van Vollenhoven R, Urowitz MB. Askanase AD, et al. Among authors: bruce in. Lupus Sci Med. 2024 May 22;11(1):e001124. doi: 10.1136/lupus-2023-001124. Lupus Sci Med. 2024. PMID: 38777595 Free PMC article. Review.
911 results